Altimmune Stock Shares Outstanding
ALT Stock | USD 7.08 0.49 6.47% |
Altimmune fundamentals help investors to digest information that contributes to Altimmune's financial success or failures. It also enables traders to predict the movement of Altimmune Stock. The fundamental analysis module provides a way to measure Altimmune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Altimmune stock.
Common Stock Shares Outstanding is likely to gain to about 55.9 M in 2024. Altimmune | Shares Outstanding |
Altimmune Company Shares Outstanding Analysis
Altimmune's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Altimmune Shares Outstanding | 70.9 M |
Most of Altimmune's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Altimmune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Altimmune Shares Outstanding Driver Correlations
Understanding the fundamental principles of building solid financial models for Altimmune is extremely important. It helps to project a fair market value of Altimmune Stock properly, considering its historical fundamentals such as Shares Outstanding. Since Altimmune's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Altimmune's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Altimmune's interrelated accounts and indicators.
Click cells to compare fundamentals
Altimmune Shares Outstanding Historical Pattern
Today, most investors in Altimmune Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Altimmune's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Altimmune shares outstanding as a starting point in their analysis.
Altimmune Shares Outstanding |
Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition |
Altimmune Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Altimmune has 70.9 M of shares currently outstending. This is 60.73% lower than that of the Biotechnology sector and 33.65% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 87.6% higher than that of the company.
Altimmune Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Altimmune's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Altimmune could also be used in its relative valuation, which is a method of valuing Altimmune by comparing valuation metrics of similar companies.Altimmune is currently under evaluation in shares outstanding category among related companies.
Altimmune Current Valuation Drivers
We derive many important indicators used in calculating different scores of Altimmune from analyzing Altimmune's financial statements. These drivers represent accounts that assess Altimmune's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Altimmune's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 24.8M | 289.2M | 378.2M | 771.9M | 599.0M | 629.0M | |
Enterprise Value | 17.6M | 175.1M | 189.4M | 662.0M | 464.5M | 487.8M |
Fund Asset Allocation for Altimmune
The fund invests 21.57% of asset under management in tradable equity instruments, with the rest of investments concentrated in bonds (15.26%) and various exotic instruments.Asset allocation divides Altimmune's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Altimmune Fundamentals
Return On Equity | -0.47 | ||||
Return On Asset | -0.25 | ||||
Operating Margin | (573.08) % | ||||
Current Valuation | 339.53 M | ||||
Shares Outstanding | 70.9 M | ||||
Shares Owned By Insiders | 0.77 % | ||||
Shares Owned By Institutions | 62.49 % | ||||
Number Of Shares Shorted | 17.73 M | ||||
Price To Earning | (1.66) X | ||||
Price To Book | 2.92 X | ||||
Price To Sales | 1,330 X | ||||
Revenue | 426 K | ||||
Gross Profit | (70.52 M) | ||||
EBITDA | (83.03 M) | ||||
Net Income | (88.45 M) | ||||
Cash And Equivalents | 184.76 M | ||||
Cash Per Share | 3.81 X | ||||
Total Debt | 671 K | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 14.12 X | ||||
Book Value Per Share | 2.75 X | ||||
Cash Flow From Operations | (76 M) | ||||
Short Ratio | 3.42 X | ||||
Earnings Per Share | (1.66) X | ||||
Target Price | 21.13 | ||||
Number Of Employees | 59 | ||||
Beta | 0.059 | ||||
Market Capitalization | 522.5 M | ||||
Total Asset | 210.64 M | ||||
Retained Earnings | (466.33 M) | ||||
Working Capital | 197.48 M | ||||
Current Asset | 13.9 M | ||||
Current Liabilities | 10.49 M | ||||
Year To Date Return | 1.67 % | ||||
One Year Return | (6.49) % | ||||
Three Year Return | (0.57) % | ||||
Net Asset | 210.64 M | ||||
Equity Positions Weight | 21.57 % | ||||
Bond Positions Weight | 15.26 % |
About Altimmune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Altimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Altimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Altimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Altimmune
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altimmune will appreciate offsetting losses from the drop in the long position's value.Moving against Altimmune Stock
0.65 | ACB | Aurora Cannabis Trending | PairCorr |
0.54 | ELYM | Eliem Therapeutics | PairCorr |
0.53 | CGC | Canopy Growth Corp Trending | PairCorr |
The ability to find closely correlated positions to Altimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altimmune to buy it.
The correlation of Altimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Altimmune Piotroski F Score and Altimmune Altman Z Score analysis. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Altimmune Stock analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Transaction History View history of all your transactions and understand their impact on performance | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.66) | Revenue Per Share 0.008 | Quarterly Revenue Growth 180 | Return On Assets (0.25) | Return On Equity (0.47) |
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Altimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.